{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T01:14:13Z","timestamp":1778807653662,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":4307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1053\/seiz.2001.0524","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T17:49:59Z","timestamp":1027878599000},"page":"505-507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["GABA and the ornithine -aminotransferase gene in vigabatrin-associated visual field defects"],"prefix":"10.1053","volume":"10","author":[{"given":"Fuki M","family":"Hisama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard H","family":"Mattson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen H","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Felice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ognen A.C","family":"Petroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/seiz.2001.0524_RF1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00971857","article-title":"Interrelationships between ornithine, glutamate, and GABA. II. Consequences of inhibition of GABA-T and ornithine aminotransferase in brain","volume":"13","author":"Daune","year":"1988","journal-title":"Neurochemical Research"},{"key":"10.1053\/seiz.2001.0524_RF2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1053\/seiz.2001.0524_RF3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bmj.314.7095.1693a","article-title":"Severe persistent visual constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin","volume":"314","author":"Mackenzie","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1053\/seiz.2001.0524_RF4","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","article-title":"Visual dysfunction in patients receiving vigabatrin. Clinical and electrophysiologic findings","volume":"53","author":"Miller","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0524_RF5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.55.1.40","article-title":"Visual function loss from vigabatrin. Effect of stopping the drug","volume":"55","author":"Johnson","year":"2000","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0524_RF6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.50.3.614","article-title":"Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings","volume":"50","author":"Krauss","year":"1998","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0524_RF7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1212\/WNL.52.6.1201","article-title":"Outer retinal dysfunction in patients treated with vigabatrin","volume":"52","author":"Arndt","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0524_RF8","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1528-1157.2000.tb00117.x","article-title":"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction","volume":"41","author":"Harding","year":"2000","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0524_RF9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1212\/WNL.55.3.347","article-title":"Separating the retinal electrophysiologic effects of vigabatrin\u2014treatment versus field loss","volume":"55","author":"Harding","year":"2000","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0524_RF10","first-page":"1694","article-title":"Severe persistent visual field constriction associated with vigabatrin. Four possible explanations exist (letter)","volume":"314","author":"Harding","year":"1997","journal-title":"British Medical Journal"},{"key":"10.1053\/seiz.2001.0524_RF11","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1212\/WNL.51.6.1779-a","article-title":"Vigabatrin-associated retinal cone dysfunction (letter). And Reply from the authors: Krauss, G.L., Johnson, M.A., and Miller, R.A","volume":"51","author":"Roubertie","year":"1998","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0524_RF12","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"1147","article-title":"The hyperornithinemias","author":"Valle","year":"1995"},{"key":"10.1053\/seiz.2001.0524_RF13","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1073\/pnas.97.3.1224","article-title":"Correction of ornithine accumulation prevents retinal degeneration in a mouse model of gyrate atrophy of the choroids and retina","volume":"97","author":"Wang","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1053\/seiz.2001.0524_RF14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0888-7543(92)90258-T","article-title":"Strand-separating conformational polymorphism analysis: efficacy of detection of point mutations in the human ornithine\u03b4 -aminotransferase gene","volume":"13","author":"Michaud","year":"1992","journal-title":"Genomics"},{"key":"10.1053\/seiz.2001.0524_RF15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1528-1157.2000.tb00227.x","article-title":"Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy","volume":"41","author":"Petroff","year":"2000","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0524_RF16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1212\/WNL.52.3.473","article-title":"Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy","volume":"52","author":"Petroff","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0524_RF17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1157.1999.tb00803.x","article-title":"Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures","volume":"40","author":"Petroff","year":"1999","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131101905242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131101905242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:22:49Z","timestamp":1761009769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131101905242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["S1059131101905242"],"URL":"https:\/\/doi.org\/10.1053\/seiz.2001.0524","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2001,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GABA and the ornithine\u03b4-aminotransferase gene in vigabatrin-associated visual field defects","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/seiz.2001.0524","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 BEA Trading, Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}